What Happened?
A number of stocks fell in the afternoon session after escalating geopolitical tensions in the Middle East sparked a surge in oil prices and stoked fears of a wider economic conflict, as Trump warned the conflict could last up to a month.
The sell-off was broad, with the Dow Jones Industrial Average falling by more than 1,000 points, while the S&P 500 and Nasdaq Composite each dropped over 2%. Investor anxiety centered on a conflict involving Iran, which reportedly led to the shutdown of the Strait of Hormuz, a critical channel for global oil shipping. The disruption sent oil prices soaring, with international benchmark Brent crude topping $84 a barrel. These higher energy costs are fueling concerns about worsening inflation, which could further pressure households and businesses, and investors are growing worried that a prolonged conflict could inflict sustained damage on the global economy.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.
Among others, the following stocks were impacted:
- Beverages, Alcohol, and Tobacco company Vita Coco (NASDAQ: COCO) fell 3.1%. Is now the time to buy Vita Coco? Access our full analysis report here, it’s free.
- Shelf-Stable Food company B&G Foods (NYSE: BGS) fell 3.5%. Is now the time to buy B&G Foods? Access our full analysis report here, it’s free.
- Household Products company Energizer (NYSE: ENR) fell 2.6%. Is now the time to buy Energizer? Access our full analysis report here, it’s free.
- Household Products company Kimberly-Clark (NASDAQ: KMB) fell 4%. Is now the time to buy Kimberly-Clark? Access our full analysis report here, it’s free.
- Household Products company Clorox (NYSE: CLX) fell 3.4%. Is now the time to buy Clorox? Access our full analysis report here, it’s free.
Zooming In On Kimberly-Clark (KMB)
Kimberly-Clark’s shares are not very volatile and have only had 2 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 4 months ago when the stock dropped 12.6% on the news that it announced a deal to acquire consumer health company Kenvue Inc. in a cash and stock transaction valued at approximately $48.7 billion.
The deal involved both cash and stock, which meant that the ownership stake for existing Kimberly-Clark shareholders was set to be diluted; they were expected to own about 54% of the combined company. The market's harsh reaction also seemed tied to Kenvue's significant legal troubles. The maker of Tylenol and Band-Aid faced lawsuits, including allegations linking Tylenol to autism and legal action over talc cancer claims. These existing issues appeared to raise concerns among investors about the risks Kimberly-Clark was taking on. Adding to the uncertainty, an investor rights law firm launched an investigation into whether the merger was fair to Kimberly-Clark's shareholders.
Kimberly-Clark is up 3.9% since the beginning of the year, but at $105.31 per share, it is still trading 28.6% below its 52-week high of $147.40 from March 2025. Investors who bought $1,000 worth of Kimberly-Clark’s shares 5 years ago would now be looking at an investment worth $806.83.
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.
